AR108233A1 - Composiciones farmacéuticas orales de nicotinamida - Google Patents

Composiciones farmacéuticas orales de nicotinamida

Info

Publication number
AR108233A1
AR108233A1 ARP170100995A ARP170100995A AR108233A1 AR 108233 A1 AR108233 A1 AR 108233A1 AR P170100995 A ARP170100995 A AR P170100995A AR P170100995 A ARP170100995 A AR P170100995A AR 108233 A1 AR108233 A1 AR 108233A1
Authority
AR
Argentina
Prior art keywords
nicotinamide
pharmaceutical compositions
oric
mesalazine
delayed
Prior art date
Application number
ARP170100995A
Other languages
English (en)
Inventor
Venkataramana Dingari
Alfred Chi Yeh Liang
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of AR108233A1 publication Critical patent/AR108233A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas para la administración oral de nicotinamida, o de una combinación de nicotinamida y mesalazina, métodos para preparar las composiciones farmacéuticas y métodos terapéuticos para usarlas. Las composiciones comprenden formulaciones de nicotinamida o de una combinación de nicotinamida y mesalazina de liberación demorada-inmediata y de liberación demorada-prolongada.
ARP170100995A 2016-04-19 2017-04-18 Composiciones farmacéuticas orales de nicotinamida AR108233A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662324415P 2016-04-19 2016-04-19

Publications (1)

Publication Number Publication Date
AR108233A1 true AR108233A1 (es) 2018-08-01

Family

ID=59227843

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100995A AR108233A1 (es) 2016-04-19 2017-04-18 Composiciones farmacéuticas orales de nicotinamida

Country Status (13)

Country Link
US (1) US11622938B2 (es)
EP (1) EP3445360B1 (es)
JP (1) JP7021108B2 (es)
KR (1) KR20180135020A (es)
CN (1) CN109152772B (es)
AR (1) AR108233A1 (es)
AU (1) AU2017252407A1 (es)
BR (1) BR112018071363A2 (es)
CA (1) CA3021066C (es)
ES (1) ES2848575T3 (es)
RU (1) RU2738114C2 (es)
TW (1) TW201739455A (es)
WO (1) WO2017184563A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426765B2 (en) 2012-06-15 2019-10-01 Conaris Research Institute Ag Pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
CA2932504A1 (en) 2013-12-13 2015-06-18 Conaris Research Institute Ag A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
US10888555B2 (en) 2013-12-13 2021-01-12 Conaris Research Institute Ag Pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
US20210236519A1 (en) * 2020-01-30 2021-08-05 Atoz Pharmaceuticals Pvt Ltd Controlled release dosage forms of 5-aminosalicylic acid and process thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791458A (fr) 1972-07-31 1973-05-16 Merck & Co Inc Produit microencapsule
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP3455544B2 (ja) 1994-06-02 2003-10-14 リガ ダン 抗ストレス剤、抗機能障害剤および抗老化剤、ならびに該薬剤の製造法
KR20000053326A (ko) 1996-11-15 2000-08-25 데이비드 엠 모이어 결장내 운반에 사용되는 다층 장용성 중합체 코팅물을 갖는 약제학적 제형
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
IT1318625B1 (it) 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
IL151150A0 (en) * 2001-01-31 2003-04-10 Roehm Gmbh Multiparticulate drug form comprising at least two differently coated pellet forms
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
TW200640497A (en) * 2005-01-21 2006-12-01 Pharmanova Inc Pharmaceutical formulations and methods of use
EP1935422A1 (en) 2006-12-20 2008-06-25 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Pharmaceutical composition comprising nicotinamide or nicotinic acid
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2009131537A1 (en) 2008-04-25 2009-10-29 Karolinska Institutet Innovations Ab New therapy of treatment of the irritable bowel syndrome.
WO2010010579A1 (en) 2008-07-19 2010-01-28 Lupin Limited Multiple unit dosage form of niacin
US20120093939A1 (en) 2008-12-17 2012-04-19 Altheus Therapeutics, Inc. Oral formulations
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
WO2013134348A1 (en) 2012-03-07 2013-09-12 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
WO2013144176A1 (en) 2012-03-30 2013-10-03 Laboratorios Del Dr. Esteve, S.A. Controlled release formulatin comprising mesalamine
US10426765B2 (en) * 2012-06-15 2019-10-01 Conaris Research Institute Ag Pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
US20140178468A1 (en) 2012-12-24 2014-06-26 Ranbaxy Laboratories Limited Multiparticulate extended-release composition of mesalamine
EP2953619A1 (en) 2013-03-15 2015-12-16 Warner Chilcott Company, LLC Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
EP3007680B1 (en) 2013-06-14 2020-02-19 CONARIS research institute AG Extended release nicotinamide formulation
US10888555B2 (en) 2013-12-13 2021-01-12 Conaris Research Institute Ag Pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
CA2932504A1 (en) 2013-12-13 2015-06-18 Conaris Research Institute Ag A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
EP3154523B1 (en) 2014-06-16 2018-11-21 Valpharma International S.P.A. Formulation for oral administration containing mesalazine
US20160045442A1 (en) 2014-08-13 2016-02-18 Cadila Healthcare Limited Stable pharmaceutical compositions of mesalamine
CN104257669A (zh) 2014-09-25 2015-01-07 合肥平光制药有限公司 一种用于向肠道递送水杨酸类药物的口服给药组合物
WO2017184566A1 (en) 2016-04-19 2017-10-26 Ferring B.V. Oral pharmaceutical compositions of mesalazine

Also Published As

Publication number Publication date
CA3021066C (en) 2024-04-09
KR20180135020A (ko) 2018-12-19
BR112018071363A2 (pt) 2019-02-05
WO2017184563A1 (en) 2017-10-26
AU2017252407A1 (en) 2018-11-01
CN109152772A (zh) 2019-01-04
US20200155461A1 (en) 2020-05-21
RU2018137323A (ru) 2020-05-19
US11622938B2 (en) 2023-04-11
EP3445360A1 (en) 2019-02-27
RU2738114C2 (ru) 2020-12-08
EP3445360B1 (en) 2020-11-11
CA3021066A1 (en) 2017-10-26
JP2019513801A (ja) 2019-05-30
TW201739455A (zh) 2017-11-16
RU2018137323A3 (es) 2020-07-13
CN109152772B (zh) 2021-09-28
ES2848575T3 (es) 2021-08-10
JP7021108B2 (ja) 2022-02-16

Similar Documents

Publication Publication Date Title
CO2017013293A2 (es) Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
IL263709A (en) Methods for the manufacture of cannabinoid prodrugs, pharmaceutical formulations and their use
EP3556369A4 (en) ORAL PHARMACEUTICAL COMPOSITION WITH DELAYED AND CONTROLLED RELEASE OF OLAPARIB AND THEIR USE
EP3256149A4 (en) FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS
MA46867A (fr) Formulations pharmaceutiques
MA42303A (fr) Formulations pharmaceutiques
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
MA55015A (fr) Formulations pharmaceutiques
IL276430A (en) A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use
EP3500291A4 (en) FORMULATIONS FOR THE ORAL ADMINISTRATION OF ACTIVE AGENTS
EP3456711A4 (en) CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREFOR
DK4023651T3 (da) Optisk aktivt pyranochromenylphenolderivat og farmaceutisk sammensætning, der omfatter samme
PH12018501758A1 (en) Oritavancin formulations
EP3497080A4 (en) PHARMACEUTICAL FORMULATIONS AND THEIR USE
MA54095A (fr) Formulations pharmaceutiques aqueuses
MA44859A (fr) Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
AR109693A1 (es) Formulaciones de liberación inmediata de oprozomib
EP3512507A4 (en) ORAL MEDICINAL FORMULATIONS

Legal Events

Date Code Title Description
FB Suspension of granting procedure